Complera FDA Approval History
FDA Approved: Yes (First approved August 10, 2011)
Brand name: Complera
Generic name: emtricitabine, rilpivirine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection
Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is a combination of three antiretroviral medications indicated for the once daily treatment of HIV-1 infection in treatment-naïve adults.
Development timeline for Complera
|Aug 10, 2011||Approval U.S. Food and Drug Administration Approves Gilead Sciences' Complera, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults|
Complera (emtricitabine, rilpivirine and tenofovir disoproxil fumarate) Consumer information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.